StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Lupron (leuprolide) [legacy through FY21] by Quarter

Lupron (leuprolide) [legacy through FY21] — International reported growth YoY (%) (%)

QuarterlyAnnual

AbbVie Lupron (leuprolide) [legacy through FY21]: 5.4% in Q4 2021, up 13.8 pts from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2021
5.4%
Period ended Dec 31, 2021
Change on a year earlier
+13.8 pts
-8.4% in Q4 2020
History
17 quarters
Since Q4 2017
Sources
17
Documents cited below

Where the Q4 2021 figure comes from

“|| Lupron | 148 | 44 | 192 | 6.1 | 5.4 | 6.0 | 5.5 | 6.0”

Source: Form 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedLupron (leuprolide) [legacy through FY21] — International reported growth YoY (%) (%)Year on yearSource
Q4 2021Dec 31, 20215.4%+13.8 ptsForm 8-K (abbv-20211231xexhibit991.htm, filed 2022-02-02) ↗
Q3 2021Sep 30, 202134.7%+52.7 ptsForm 8-K (abbv-20210930xexhibit991.htm, filed 2021-10-29) ↗
Q2 2021Jun 30, 202123.9%+32.8 ptsForm 8-K (abbv-20210630xexhibit991.htm, filed 2021-07-30) ↗
Q1 2021Mar 31, 202110.8%+8.7 ptsForm 8-K (abbv-20210331xexhibit991.htm, filed 2021-04-30) ↗
Q4 2020Dec 31, 2020-8.4%-24.9 ptsForm 8-K (abbv-20201231xexhibit991.htm, filed 2021-02-03) ↗
Q3 2020Sep 30, 2020-18.0%-24.2 ptsForm 8-K (abbv-20200930xex991.htm, filed 2020-10-30) ↗
Q2 2020Jun 30, 2020-8.9%-12.1 ptsForm 8-K (abbv-20200630xexhibit991.htm, filed 2020-07-31) ↗
Q1 2020Mar 31, 20202.1%+3.5 ptsForm 8-K (abbv-20200331xexhibit9.htm, filed 2020-05-01) ↗
Q4 2019Dec 31, 201916.5%+17.4 ptsForm 8-K (abbv-20191231xexhibit9.htm, filed 2020-02-07) ↗
Q3 2019Sep 30, 20196.2%-1.0 ptsForm 8-K (abbv-20190930xexhibit991.htm, filed 2019-11-01) ↗
Q2 2019Jun 30, 20193.2%-7.8 ptsForm 8-K (abbv-20190630xexhibit991.htm, filed 2019-07-26) ↗
Q1 2019Mar 31, 2019-1.4%-3.9 ptsForm 8-K (abbv-20190331xexhibit991.htm, filed 2019-04-25) ↗
Q4 2018Dec 31, 2018-0.9%-4.2 ptsForm 8-K (abbv-20181231xexhibit991.htm, filed 2019-01-25) ↗
Q3 2018Sep 30, 20187.2%–Form 8-K (abbv-20180930xexhibit991.htm, filed 2018-11-02) ↗
Q2 2018Jun 30, 201811.0%–Form 8-K (abbv-20180630xexhibit991.htm, filed 2018-07-27) ↗
Q1 2018Mar 31, 20182.5%–Form 8-K (abbv-20180331xexhibit991cl.htm, filed 2018-04-26) ↗

Cite this data

StockData. (2026). AbbVie Lupron (leuprolide) [legacy through FY21] (%), quarterly Q4 2017–Q4 2021 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lupron-intl-rep-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.